Impact of proton pump inhibitors on cytochrome P450 activity assessed by 13C-aminopyrine breath test in patients with cirrhosis was written by Rocco, Alba;Compare, Debora;Sgamato, Costantino;Coccoli, Pietro;Chiodini, Paolo;Nardone, Gerardo. And the article was included in Alimentary Pharmacology and Therapeutics in 2021.Application In Synthesis of Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide The following contents are mentioned in the article:
Summary : Background : Chronic use of proton pump inhibitors (PPIs) in patients with impaired liver function may worsen cytochrome P 450 (CYP450) activity, predisposing them to clin. relevant drug-drug interactions. The 13C-aminopyrine breath test (13C-ABT) is a non-invasive tool to study CYP450-dependent liver function. Aims : To assess 13C-ABT modifications with different PPIs in patients with cirrhosis. Methods : Sixty consecutive patients with HCV-related cirrhosis and indication to start PPI therapy were randomised to receive omeprazole 20 mg/day, esomeprazole 20 mg/day, lansoprazole 15 mg/day, pantoprazole 40 mg/day or rabeprazole 20 mg/day. 13C-ABT was performed at baseline and on the 15th day of PPI therapy. Results : At baseline, mean values of max 13C% dose/h and 13C% cum dose at 120 min did not differ significantly among groups. On the 15th day of therapy, max 13C% dose/h and 13C% cum dose at 120 min did not significantly differ with respect to baseline for pantoprazole (P = 0.184 and P = 0.309, resp.) or rabeprazole (P = 0.536 and P = 0.286, resp.), but were significantly decreased on omeprazole (P = 0.013 and P = 0.015, resp.), esomeprazole (P = 0.009 and P = 0.001, resp.), and lansoprazole (P = 0.033 and P = 0.035, resp.). Conclusions : In patients with cirrhosis, omeprazole, esomeprazole and lansoprazole inhibit microsomal activity while pantoprazole and rabeprazole do not have a significant impact. Should our data be confirmed in larger cohort studies, pantoprazole and rabeprazole could be safely recommended for patients with cirrhosis. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Application In Synthesis of Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide).
Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole has become an important synthon in the development of new drugs. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Application In Synthesis of Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem